Keywords: Orexigen, Contrave, Obesity, USA, FDA

Orexigen slumps as FDA calls for more studies with obesity drug Contrave

Article | 02 February 2011

Print This

Shares of US biotech firm Orexigen Therapeutics (Nasdaq: OREX) plunged more than 70% to $2.47 in pre-market trading Tuesday, as the company ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in